Tongji Hospital Affiliated of Tongji Medical College Huazhong University of Science and Technology
Welcome,         Profile    Billing    Logout  
 0 Trials 
10 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
xiong, huihua
RC48-C012, NCT04400695: A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2

Recruiting
3
366
RoW
RC48-ADC, RC48, Paclitaxel Injection, Taxol, Docetaxel Injection, Taxotere, Vinorelbine Tartrate Injection, Navelbine, Capecitabine Tablets, Xeloda
RemeGen Co., Ltd.
Breast Cancer
06/24
12/24
TORCHLIGHT, NCT04085276: Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment

Active, not recruiting
3
531
RoW
JS001, Nab-Paclitaxel, Placebo
Shanghai Junshi Bioscience Co., Ltd.
Triple-Negative Breast Cancer
12/24
12/25
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
TQB2102-III-01, NCT06561607: A Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer

Not yet recruiting
3
542
RoW
TQB2102 for Injection, Chemotherapy drug (Capecitabine/Paclitaxel/Albumin Paclitaxel)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Breast Cancer
01/27
12/28
RC48-C006, NCT03500380: A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases

Active, not recruiting
2/3
301
RoW
RC48-ADC, RC48, Lapatinib, Capecitabine
RemeGen Co., Ltd.
Breast Neoplasms, Breast Diseases, Capecitabine, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma, HER2-positive Advanced Breast With Liver Metastases
07/24
12/24
NCT05145907: Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors

Active, not recruiting
2
133
RoW
TJ107 +Pembrolizumab
TJ Biopharma Co., Ltd.
Triple-negative Breast Cancer, Head and Neck Squamous Cell Carcinoma
06/24
12/24
NCT06149130: Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+/HER2 - Advanced Breast Cancer

Recruiting
2
82
RoW
Adebrelimab, SHR-1316, dalpiciclib, SHR-6390
Tongji Hospital
Breast Cancer
11/25
11/26
UTILIZABLE, NCT06125080: The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer () ：Single-arm, Prospective, Open Clinical Study

Recruiting
2
78
RoW
Utidelone, UTD1, Tirelizumab, Bevacizumab
Huihua Xiong
TNBC - Triple-Negative Breast Cancer
10/25
10/26
NCT05746728: Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer

Not yet recruiting
1/2
45
RoW
Surufatinib, Tislelizumab
Huihua Xiong
Metastatic Triple-negative Breast Cancer
08/24
08/25
tengfei, Chao
NCT06152822: Pyrotinib Combined With Capecitabine and Bevacizumab for Patients With HER2 Positive Breast Cancer and Brain Metastases

Recruiting
2
30
RoW
pyrotinib+capecitabine+bevacizumab
Tongji Hospital
Breast Cancer With Brain Metastases
11/24
11/25

Download Options